Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.
The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.
Study Type
OBSERVATIONAL
Enrollment
40
Acıbadem Labcell Cellular Therapy Laboratories
Istanbul, Turkey (Türkiye)
RECRUITINGAcibadem Altunizade Hospital
Istanbul, Turkey (Türkiye)
RECRUITINGMortality Rate
A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval.
Time frame: 6 Months
Length of Hospitalization
The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency
Time frame: 6 Months
Side Effects
Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect.
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.